Ascendiant Capital

Analysts at Ascendiant Capital downgraded Cytori Therapeutics (NASDAQ: CYTX) from Buy to Hold and removed the price target of $4.00. Cytori Therapeutics shares have dropped 21.93% over the past 52 weeks, while the S&P 500 index has gained 13.56% in the same period. Cytori Therapeutics' shares...

In a report published Friday, Ascendiant Capital analyst Christopher Bamman downgraded the rating on DXP Enterprises (NASDAQ: DXPE) from Buy to Neutral, and removed the $71.00 price target. In the report, Ascendiant Capital noted, “We are lowering our rating on the shares of DXP Enterprises to...

In a report published Wednesday, Ascendiant Capital analyst Marla Backer initiated coverage on Cinemark Holdings (NYSE: CNK) with a Buy rating and $32.00 price target. In the report, Ascendiant Capital noted, “Cinemark operates in some of the fastest growing U.S. markets and is also a leading...

In a report published Wednesday, Ascendiant Capital analyst Keay Nakae reiterated a Buy rating on Biolase (NASDAQ: BIOL), but lowered the price target from $6.50 to $5.50. In the report, Ascendiant Capital noted, “We continue to believe that Biolase is well positioned in the dental laser market....

In a report published on Monday, Ascendiant Capital analyst Elizabeth Pierce initiated coverage on First Cash Financial Services (NASDAQ: FCFS) with a Strong Buy rating and a $65 price target. In the report, Ascendiant Capital stated, “Although the recent volatility in gold has impacted near-...

In a report published Friday, Ascendiant Capital analyst Carter W. Driscoll initiated coverage on American Superconductor (NASDAQ: AMSC) with a Buy rating and $3.25 price target. In the report, Ascendiant Capital noted, “We are initiating coverage with a BUY and $3.25 target. AMSC is a leading...

In a report published on Wednesday, Ascendiant Capital analyst Marla Backer initiated coverage on Regal Entertainment Group (NYSE: RGC) with a Buy rating a $21 price target. In the report, Ascendiant Capital stated, "Well positioned. As the industry's largest player, we believe Regal is well...

In a report published Wednesday, Ascendiant Capital analyst Edward Woo initiated coverage on Orbitz Worldwide (NYSE: OWW) with a Buy rating and $10.00 price target. In the report, Ascendiant Capital noted, “We believe that the company's position as one of the world's leading OTAs will continue...

In a report published Wednesday, Ascendiant Capital analyst Edward Woo reiterated a Buy rating on GameStop (NYSE: GME), and raised the price target from $44.00 to $46.00. In the report, Ascendiant Capital noted, “The major video game industry convention E3 took place last week in Los Angeles....

In a report published Wednesday, Ascendiant Capital analyst Elizabeth Pierce reiterated a Strong Buy rating on The Wet Seal (NASDAQ: WTSL), and raised the price target from $6.50 to $7.00. In the report, Ascendiant Capital noted, “Based on Q1 results and Q2 guidance, we believe WTSL's...

In a report published Friday, Ascendiant Capital analyst Carter W. Driscoll initiated coverage on Polypore International (NYSE: PPO) with a Neutral rating and $45.50 price target. In the report, Ascendiant Capital noted, “Innovation and design of microporous membranes is core sustainable...

In a report published Friday, Ascendiant Capital analyst Edward Woo reiterated a Buy rating on GameStop Corp. (NYSE: GME), and raised the price target from $34.00 to $44.00. In the report, Woo noted, “GameStop will report Q1 2013 (April) results before market open on Thursday, May 23 with a...

In a report published Thursday, Ascendiant Capital analyst Christopher Bamman downgraded the rating on Crane Co. (NYSE: CR) from Buy to Hold. In the report, Bamman noted, “Crane Co. shares have gained approximately 30% so far in 2013. Given the strong price performance, we believe it to be prudent...

In a report published Thursday, Ascendiant Capital analyst George Santana initiated coverage on Ocean Power Technologies (NASDAQ: OPTT) with a Strong Buy rating and $5.00 price target. In the report, Santana noted, “The company is currently valued at a negative Enterprise Value. In our view, this...

In a report published Friday, Ascendiant Capital analyst Keay Nakae downgraded the rating on Solta Medical (NASDAQ: SLTM) from Strong Buy to Buy, and lowered the price target from $3.50 to $2.25. In the report, Nakae noted, “We believe that Solta has now become a ‘show me' stock. While we continue...